<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Molecular and Cellular Medicine</title>
<title_fa>مجله بین المللی سلولی و مولکولی</title_fa>
<short_title>Int J Mol Cell Med</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijmcmed.org</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2251-9637</journal_id_issn>
<journal_id_issn_online>2251-9645</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.22088/IJMCM.BUMS</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1404</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2025</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>14</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Counting Copies, Making Medicines: A Roadmap for the MSC-EV-microRNAome</title>
	<subject_fa>Cell Biology</subject_fa>
	<subject>Cell Biology</subject>
	<content_type_fa>Editorial</content_type_fa>
	<content_type>Editorial</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;span style=&quot;font-size:12pt&quot;&gt;&lt;span style=&quot;line-height:200%&quot;&gt;&lt;span sans-serif=&quot;&quot; style=&quot;font-family:Calibri,&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;Mesenchymal stromal cell&amp;ndash;derived extracellular vesicles (MSC-EVs) are promising candidates for cell-free therapeutics, but the copy-number mathematics -most EVs contain fewer than one copy of a given microRNA (miRNA)- forces a reconsideration of mechanisms and development strategies. Translation will require disciplined adherence to MISEV2023 standards: definitions of transparent source and separation; absolute quantification of cargo by digital PCR (dPCR) or UMI-aware small RNA sequencing; and validated potency assays (e.g., NF-&amp;kappa;B suppression, macrophage polarization) linked to critical quality attributes (CQAs). Dosing should evolve from particle/protein counts to a triad of particles, protein, and miRNA copies, ideally tied to activity-based units. Clean separations are essential to avoid misattributing effects to vesicles in the presence of non-vesicular RNA. Safety assessment, including TF/CD142 and thrombogenicity, must guide route selection. Manufacturing should standardize CPP-to-CQA control in TFF-based systems, while stability testing must minimize freeze&amp;ndash;thaw cycles and validate lyophilization. The first approvable product will likely use local delivery, a small number of defined miRNAs, and copy-number-anchored dosing. The translational mandate is clear: count molecules, link counts to function, and dose based on biology.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&amp;nbsp;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Mesenchymal stromal cells (MSCs), Extracellular vesicles (EVs), microRNA (miRNA), MSC-EV-microRNAome, MISEV2023</keyword>
	<start_page>793</start_page>
	<end_page>796</end_page>
	<web_url>http://ijmcmed.org/browse.php?a_code=A-10-85-5&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Farshid</first_name>
	<middle_name></middle_name>
	<last_name>Yeganeh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>fyeganeh@gmail.com</email>
	<code>100319475328460035441</code>
	<orcid>100319475328460035441</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Hadi</first_name>
	<middle_name></middle_name>
	<last_name>Parsian</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>hadiparsian@yahoo.com</email>
	<code>100319475328460035442</code>
	<orcid>100319475328460035442</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
